Immutep Completes FDA Project Optimus, Advances Efti Trials

Immutep ( (IMMP) ) just unveiled an announcement.

Immutep Limited announced on October 13, 2025, the successful completion of the FDA’s Project Optimus requirements, confirming 30mg as the optimal biological dose for its immunotherapy candidate eftilagimod alfa (efti). This milestone is strategically significant for Immutep’s oncology programs and paves the way for future Biological License Applications. The completion of Project Optimus also facilitates the opening of clinical sites in the United States for the TACTI-004 (KEYNOTE-F91) Phase III trial, which evaluates efti in combination with MSD’s KEYTRUDA® and chemotherapy for first-line treatment of advanced non-small cell lung cancer.

The most recent analyst rating on (IMMP) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Immutep stock, see the IMMP Stock Forecast page.

Spark’s Take on IMMP Stock

According to Spark, TipRanks’ AI Analyst, IMMP is a Neutral.

Immutep’s overall stock score is primarily influenced by its challenging financial performance, marked by persistent losses and negative cash flows. The technical analysis provides some positive momentum, but the valuation remains unattractive due to a negative P/E ratio and lack of dividend yield. The absence of earnings call data and corporate events means these factors do not impact the score.

To see Spark’s full report on IMMP stock, click here.

More about Immutep

Immutep is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company is a leader in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), aiming to leverage this expertise to provide innovative treatment options and maximize shareholder value.

Average Trading Volume: 98,174

Technical Sentiment Signal: Buy

Current Market Cap: $292.4M

For a thorough assessment of IMMP stock, go to TipRanks’ Stock Analysis page.